Business
Clinical Advisory Board and Update on Modi-1
Clinical Advisory Board and Update on Modi-1.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 5878Y Scancell Holdings Plc 10 May 2019 \n\n10 May 2019\n \nScancell Holdings Plc\n(\"Scancell\" or the \"Company\")\n \nScancell Establishes Clinical Advisory Board and Provides Update on Modi-1 Progress\n \nAppoints six world class clinical oncologists to guide the Moditope® clinical development strategy\n \nModi-1 manufacturing and toxicity testing underway to support anticipated start of Phase 1/2 study in \nQ1 2020\n \nScancell Holdings plc, the developer of novel immunotherapies for the treatment of cancer, today announces that it has appointed six world-leading clinicians to establish its Clinical Advisory Board (\"CAB\"). The Board will be chaired by Professor Robert Coleman and will provide strategic guidance and support as the Company prepares for its lead Moditope® candidate, Modi-1, to enter the clinic in Q1 2020 in multiple tumour types, including head and neck, breast and ovarian cancer.\n \nThe CAB comprises: Professor Robert Coleman, Emeritus Professor of Medical Oncology at Weston Park Hospital and the University of Sheffield; Professor Christian Ottensmeier, Professor of Experimental Cancer Medicine at the University of Southampton; Professor Poulam Patel, Professor of Clinical Oncology at the University of Nottingham and Honorary Consultant Medical Oncologist at the Nottingham University Hospitals NHS Trust; Professor Iain McNeish, Professor of Oncology and Head of the Division of Cancer within the Department of Surgery and Cancer, Imperial College London; Professor David Miles, Lead Clinician for breast cancer at Mount Vernon Cancer Centre; and Professor Stephen Chan, Director of Clinical Trials in Breast Cancer and Gynaecological Cancer at Nottingham University Hospital.\n \nThe Company also provides an update on progress towards initiating the Modi-1 Phase 1/2 clinical trial.\n \n· Good Manufacturing Practice (GMP) synthesis of the bulk Modi-1 peptide conjugates is underway at the PolyPeptide Group's facilities in The Netherlands.\n \n· The Company signed an agreement at the end of April 2019 with AMRI (Glasgow, UK), a global contract and manufacturing organisation, to formulate, manufacture and package the Modi-1 GMP final product for clinical testing.\n \n·  ...